Shire exec to head up Servier's US subsidiary

Having recently acquired the oncology business  of Shire (LSE: SHP) for $2.4 billion, leading independent French drugmaker Servier has now also acquired a senior executive of the company, which is in the process of being acquired by Japan’s Takeda (TYO; 4502).

Servier has appointed David Lee as chief executive of its new US commercial subsidiary, Servier Pharmaceuticals (Boston, US).

As part of his new role, Mr Lee will be responsible for developing a strong commercial presence in the USA with the existing portfolio to be enriched with close-to-market or marketed innovative products, in line with the Group’s strategy. He will report to Olivier Laureau, president of the Servier group. This appointment is part of a definitive agreement to acquire Shire’s oncology business and will take effect upon closing of the transaction, following clearance by the relevant merger control authorities.